StockData
Zymeworks Inc. logo

Zymeworks Inc. (ZYME) stock

ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30667% above fair value
$26.04+0.20 (+0.77%)

Close on Nov 18, 2026Market cap $1.85BP/E –Yield –

Zymeworks free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Zymeworks's free cash flow for the twelve months ending Jun 30, 2026 was -$120.54M. For fiscal 2025 it was -$34.53M. The highest annual figure on record is $135.96M in fiscal 2022.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$34.53M–
FY2024Dec 31, 2024-$112.05M–
FY2023Dec 31, 2023-$120.80M-188.8%
FY2022Dec 31, 2022$135.96M–
FY2021Dec 31, 2021-$204.86M–
FY2020Dec 31, 2020-$155.71M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$31.95M-376.4%
Q1 FY2026Mar 31, 2026-$45.93M–
Q4 FY2025Dec 31, 2025-$10.84M–
Q3 FY2025Sep 30, 2025-$31.82M–
Q2 FY2025Jun 30, 2025$11.56M–
Q1 FY2025Mar 31, 2025-$3.42M–
Q4 FY2024Dec 31, 2024-$41.82M-408.1%
Q3 FY2024Sep 30, 2024-$6.78M–
Q2 FY2024Jun 30, 2024-$25.59M–
Q1 FY2024Mar 31, 2024-$37.86M–
Q4 FY2023Dec 31, 2023$13.58M-95.8%
Q3 FY2023Sep 30, 2023-$43.60M–
Q2 FY2023Jun 30, 2023-$7.20M–
Q1 FY2023Mar 31, 2023-$83.58M–
Q4 FY2022Dec 31, 2022$327.01M–
Q3 FY2022Sep 30, 2022-$74.00M–
Q2 FY2022Jun 30, 2022-$57.49M–
Q1 FY2022Mar 31, 2022-$59.57M–
Q4 FY2021Dec 31, 2021-$55.29M–

More Zymeworks figures

See a number that looks wrong?